Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening

@article{Andreassi2006FactorVL,
  title={Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening},
  author={Maria Grazia Andreassi and Nicoletta Botto and Silvia Maffei},
  journal={Clinical Chemistry and Laboratory Medicine (CCLM)},
  year={2006},
  volume={44},
  pages={514 - 521}
}
Abstract Venous thromboembolism is a well-known complication of oral contraception and hormonal replacement therapy. Inherited thrombophilia is viewed as an important determinant in modulating the effects of estrogens on thrombotic risk. An increasing number of kits for thrombophilic mutations [factor V Leiden, G20210A prothrombin and methylenetetrahydrofolate reductase (MTHFR) C677T genes] are becoming commercially available, and screening for inherited thrombotic risk is among the most… Expand
Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy
TLDR
A positive family history of thrombosis is a sensitive indicator for selected genetic testing in high-risk women before starting HRT. Expand
Factor V Leiden and Prothrombin G20210A Mutations Among Healthy Indians in Malaysia
Background: Factor V Leiden (FVL) (G1691A) and prothrombin gene (G20210A) mutations are the 2 most common inherited forms of thrombophilia. The prevalence of these 2 mutations is known to show aExpand
Point Mutation in Factor V Leiden G 1691 A and Factor II G 20210 A and Effect on Coagulation Profile and Frequency of Recurrent Spontaneous Abortions among Sudanese Women
Objective: To investigate the effect of point mutation in FV Leiden G1691A and FII G20210A gene on coagulation and recurrent spontaneous abortion (RSA) among Sudanese women. Study Design: This wasExpand
Genetic correlation between Prothrombin G20210A polymorphism and retinal vein occlusion risk
TLDR
Based on integrated analysis of the current evidence, Prothrombin gene G20210A polymorphism is likely unrelated to the risk of RVO and Statistically stable results were observed in the sensitivity analyses. Expand
Ricadute sull'appaRato caRdio-vascolaRe delle diffeRenti foRme di teRapia oRmonale sostitutiva nelle donne in menopausa
TLDR
When women are older and/or already affected by atherogenic burden, ischemic coronary events and stroke are increased by estrogen plus progestin therapy, especially in the first year of treatment (“early harm”) due to adverse hepatocellular effects of oral estrogen on coagulant cascade and inflammation as a consequence of the first liver passage. Expand
The emotional impact of genetic testing and aspects of counseling prior to prescription of oral contraceptives.
TLDR
Testing for factor V Leiden has considerable emotional impact and Recommendations after testing are not consistently driven by the test result. Expand
Disappearing Inferior Vena Cava in A Pediatric Patient with Down Syndrome and Hereditary Thrombophilia
TLDR
It is proposed that during a period of six months, inferior vena cava first occluded, then become redundant in a baby girl with several chromosomal and gene defects, including Down syndrome and hereditary thrombophilia, admitted to the hospital due to the swelling and redness of the right lower extremity. Expand
The Promise of Individualized Therapy
TLDR
The issues related to pharmacogenetics and pharmacogenomics are the two recent developments to investigate inter-individual variations of drug response. Expand
Marcatori genetici di rischio cardiovascolare (Rassegna)
Nel corso degli ultimi anni, la ricerca genetica ha dato risultati per l’applicazione clinica soprattutto sulle malattie cosiddette semplici o mendeliane, che sono determinate dalla mutazione in unExpand
...
1
2
...

References

SHOWING 1-10 OF 92 REFERENCES
Genetic testing for thrombophilia mutations.
  • M. Hertzberg
  • Biology, Medicine
  • Seminars in thrombosis and hemostasis
  • 2005
TLDR
It is shown that the new, semiautomated methodologies of real-time polymerase chain reaction and DNA microarrays offer the potential for widespread application and utility in the future. Expand
Laboratory investigation of thrombophilia.
Until recently, laboratory diagnosis of thrombophilia was based on investigation of the plasmatic anticoagulant pathways to detect antithrombin, protein C, and protein S deficiencies and on theExpand
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials. Expand
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis
TLDR
It is concluded that the thrombosis risk of HRT may particularly affect women with prothrombotic mutations, and efforts to avoid HRT in women with increased risk of thromBosis are advisable. Expand
Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism.
TLDR
It is concluded that FVL and the PT-20210A are risk factors for VT as well as Hcy levels, but the MTHFR and PAI-1 polymorphisms do not appear to be associated with VT in this country. Expand
Thrombophilia in young women candidate to the pill: reasons for and against screening
TLDR
General screening with genetic testing for inherited thrombophilia can be recommended before oral contraception, and a pharmacogenetics approach in prescribing OC on the basis of each woman's genetic make-up could increase drug safety. Expand
Laboratory detection of inherited thrombophilia: a historical perspective.
  • P. Mannucci
  • Medicine
  • Seminars in thrombosis and hemostasis
  • 2005
TLDR
It is hoped that because the authors currently have such simple and clinically useful global tests of hypocoagulability as the prothrombin time and activated partial thromboplastin time, it may soon become possible to measure multifactorialThrombophilia without resorting to the multiplicity of tests now necessary. Expand
Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.
TLDR
It is concluded that carriers of the prothrombin mutation who use oral contraceptives have a markedly increased risk of deep vein thrombosis, much higher than the risk conferred by either factor alone. Expand
INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.
  • O. Egeberg
  • Medicine
  • Thrombosis et diathesis haemorrhagica
  • 1965
TLDR
The results strongly suggest that antithrombin III and heparin cofactor are actually the same factor or plasma substance and that deficiency of this antithROMbin factor can cause a severe tendency toward thrombosis. Expand
Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism.
TLDR
It is unlikely that confounding by indication entirely explains the risk of VTE associated with third generation OCs since the combined effect exceeds what could be explained if this source of error was the only determinant of the association. Expand
...
1
2
3
4
5
...